Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AB598 |
Synonyms | |
Therapy Description |
AB598 is an inhibitory ENTPD1 (CD39) antibody, which potentially stimulates immune activity in the tumor microenvironment (Cancer Immunol Res (2022) 10 (12_Supplement): B08). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB598 | AB 598|AB-598 | CD39 Antibody 5 | AB598 is an inhibitory ENTPD1 (CD39) antibody, which potentially stimulates immune activity in the tumor microenvironment (Cancer Immunol Res (2022) 10 (12_Supplement): B08). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05891171 | Phase I | AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) | Recruiting | USA | AUS | 0 |